Aspirin on the prevention of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis”
Abstract
dysfunction-associated steatotic liver disease; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis;
Fields of Study & Subjects
Liver Disease Diagnosis and Treatment
Hepatocellular Carcinoma Treatment and Prognosis
Inflammatory mediators and NSAID effects
Publication details
- Journal / source
- Clinical and Molecular Hepatology
- Volume
- 32
- Issue
- 3
- Pages
- 1433–1436
- Publication date
- 27 January 2026
- Language
- EN